Replimune skin cancer drug that became FDA flashpoint is rejected again - statnews.com

Replimune skin cancer drug that became FDA flashpoint is rejected again - statnews.com
Business

Listen to this article

0%

The Food and Drug Administration on Friday rejected again an experimental treatment for advanced skin cancer developed by Replimune Group.Β  Replimunes treatment, an engineered virus designed to rev … [+678 chars]

Leave A Comment

Comments are moderated and may take time to appear.

Comments

No comments yet. Be the first to comment!

Stay Connected